CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

24/02/2026

1

Speculative Buy

$6.40

87.68%

Bell Potter highlights ongoing progress in Clarity Pharmaceuticals' Secure phase II expansion study.

A 76-year-old patient achieved an undetectable prostate-specific antigen (PSA) seven weeks after the first dose of 67Cu-SAR-bisPSMA. No disease was observed on follow-up imaging and only mild adverse events reported, note the analysts.

The broker highlights five complete responders from around 35-40 treated patients to date. This is thought to compare favourably to a 9% complete response rate in Pluvicto’s (Novartis’ radioligand therapy for prostate cancer) phase III study.

Upcoming Co-PSMA data is expected to demonstrate improved specificity and act as a key catalyst.

Buy rating and $6.40 target price are maintained.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -18.70 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -16.60 cents.

19/02/2026

1

Buy

$9.00

163.93%

Canaccord Genuity reiterates its Buy rating and $9.00 target following the release of Co-PSMA trial results, which the broker describes as clinically meaningful.

The head-to-head study showed 64Cu-SAR-bisPSMA detected 78% of lesions versus 36% for 68Ga-PSMA-11, with statistically superior mean lesions per patient and a 44% change in planned management.

Canaccord believes the data reinforces 64Cu-SAR-bisPSMA as a clinically superior second-generation PSMA PET tracer in biochemical recurrent prostate cancer, particularly at low PSA levels where detection is critical for salvage radiotherapy decisions.

An estimated circa 150k additional patients could benefit, supporting incremental US$250m peak sales and total peak sales of US$750–800m, which are already incorporated in forecasts. 

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -26.90 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -34.60 cents.